Beyond THC and CBD: Minor Cannabinoids in Clinical Practice - Bonni Goldstein, MD

Tags: CBG, Cannabigerol, CBDA, THCA, CBDV, Glioblastoma, Neuroinflammation, Cannabis Research, Medicine

Bonni Goldstein, MD, presents "Beyond THC and CBD: Minor Cannabinoids in Clinical Practice" at CannMed 23.

0:00 Intro
0:56 Phytocannabinoid Synthesis
1:40 CBG Targets
2:20 TRP Channels
3:37 CBG: Anti-Cancer
6:35 CBG: Reduces Neuroinflammation
7:18 CBG: Analgesic
7:36 CBG: Appetite Simulation
8:17 CBG: Metabolic Homeostasis
9:10 CBG: Anti-Psoriatic / Skin Effects
9:33 CBG: Anxiety / Depression
10:00 CBDA Targets
11:31 CBDA Anticonvulsant Effects
14:35 CBDA
15:45 CBDA: Patient Report
18:29 Targets of THCA
20:48 THCA: Patient Report
24:50 CBDV Targets
29:48 CBDV: Patient Report
32:44 Q&A

Although research on phytocannabinoids has focused on THC and CBD, the so-called “minor” cannabinoids have become readily available and are being employed by patients to treat medical conditions, as well as being added to wellness regimens. What do we know about the minor cannabinoids and what conditions might benefit from them? Dr. Goldstein will review the mechanisms of action for CBG, CBDA, THCA and CBDV, the latest scientific findings, as well as her experience using these compounds in clinical practice.

Learn More about CannMed: https://cannmedevents.com/